Kenneth T. Mills Sells 10,000 Shares of REGENXBIO Inc. (RGNX) Stock
REGENXBIO Inc. (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $27.71, for a total value of $277,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of REGENXBIO Inc. (RGNX) traded up $1.30 during trading on Tuesday, reaching $29.10. The company had a trading volume of 284,376 shares, compared to its average volume of 278,400. REGENXBIO Inc. has a 1 year low of $16.30 and a 1 year high of $36.10.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.04. The firm had revenue of $1.34 million during the quarter. REGENXBIO had a negative return on equity of 39.33% and a negative net margin of 764.06%. analysts predict that REGENXBIO Inc. will post -2.71 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its position in REGENXBIO by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 2,011 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in REGENXBIO in the 3rd quarter worth about $328,000. Ardsley Advisory Partners acquired a new position in REGENXBIO in the 2nd quarter worth about $197,000. American International Group Inc. increased its position in REGENXBIO by 7.1% in the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 822 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new position in REGENXBIO in the 2nd quarter worth about $249,000. 72.09% of the stock is owned by hedge funds and other institutional investors.
RGNX has been the subject of several recent analyst reports. BidaskClub raised REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Zacks Investment Research raised REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Saturday, August 12th. Evercore ISI began coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $34.00 target price on shares of REGENXBIO in a report on Thursday, November 9th. Finally, Bank of America Corporation upped their target price on REGENXBIO from $29.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. REGENXBIO presently has a consensus rating of “Buy” and a consensus target price of $43.17.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.